Tech Meridian ← ENTITY INDEX
PROMY MERIDIAN RU

COMPANY · ENTITY #32312

Žiga Avsec

Related event timeline, sources and context from the news index.

EVENT TIMELINE

3

MODELS · 1 SOURCE · Google

DeepMind's AlphaGenome model and AlphaGenome Atlas provide genome-wide variant impact predictions

Google DeepMind's AlphaGenome is a predictive model that analyzes up to 1 million base-pair sequences and was used to generate the AlphaGenome Atlas, a dataset of predicted effects for all ~9 billion single-nucleotide changes; the Atlas provides a single AVI (AlphaGenome Variant Impact) score to help researchers prioritize variants. DeepMind launched AlphaGenome in June 2025 and introduced AlphaGenome Atlas in September 2025, and early users at institutions like the University of Exeter and the Broad Institute report using AVI to narrow candidate variants in research.

8.0

MODELS · 2 SOURCES · The Verge AI · The Decoder

DeepMind releases AlphaGenome 2 to predict cell-type‑specific effects of genetic variants

DeepMind unveiled AlphaGenome 2, a successor to AlphaGenome that predicts how DNA variants affect specific cell types and states. Trained on over 100 million single-cell profiles across 68 tissues, the model reportedly detects nearly twice as many expression-altering variants as the prior state of the art and is being made available for non-commercial research via the AlphaGenome API with a limited private preview for commercial use.

8.0

MODELS · 1 SOURCE · Google DeepMind

AlphaGenome 2: conditional DNA sequence model predicts variant effects in specific cell types

AlphaGenome 2 is a next-generation DNA-sequence model that predicts how sequence variants affect molecular readouts (gene expression, chromatin accessibility, histone marks, DNA methylation) in specific human cell types and states. Trained on over 107 million individual cell profiles across 68 tissues, it uses a conditional architecture that takes a biological condition plus a DNA sequence, improves detection of cell-type–specific regulatory variants versus the prior model, supports cross-modality imputation, and is available for non-commercial research via the AlphaGenome API (commercial preview private).

8.0